No effect of Implanon® on inflammatory cardiovascular parameters

Gynecological Endocrinology

Volumn 27, Issue 11, 2011, Pages 951-955

  Merki Feld, Gabriele S ^a   Rosselli, Marinella ^a   Imthurn, Bruno ^a   Spanaus, Katharina ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

adiponectin; cardiovascular risk; Contraception; desogestrel; hormonal contraception; IL 6; Implanon ; inflammatory markers; progestagens

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; ESTRADIOL; ETONOGESTREL; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LIPOPROTEIN A; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CONTRACEPTIVE DEVICE; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; HUMAN; HUMAN EXPERIMENT; IMPLANT; INFLAMMATION; LIPID BLOOD LEVEL; MENSTRUAL CYCLE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADOLESCENT; ADULT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; FEMALE; HUMANS; INTERLEUKIN-6; LIPOPROTEIN(A); PROGESTERONE CONGENERS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 80053995351     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.564684     Document Type: Article

References (30)

1. Speroff L, Fritz M. Clinical gynecologic endocrinology and infertility. 2005;1:861-942.
2. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:2890.
3. Doring A, Frohlich M, Lowel H, Koenig W. Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 2004;172:281-286. (Pubitemid 38167539)
4. Lidegaard O. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol 1999;180:S357-S363. (Pubitemid 29293241)
5. Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999;4:67-73. (Pubitemid 29318065)
6. Nishida M, Moriyama T, Ishii K, Takashima S, Yoshizaki K, Sugita Y, Yamauchi-Takihara K. Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis. Clin Chim Acta 2007;384:99-104. (Pubitemid 47248651)
7. Kunnari A, Santaniemi M, Jokela M, Karjalainen AH, Heikkinen J, Ukkola O, Kesaniemi YA. Estrogen replacement therapy decreases plasma adiponectin but not resistin in postmenopausal women. Metabolism 2008;57:1509-15.
8. Djurovic S, Os I, Hofstad AE, Abdelnoor M, Westheim A, Berg K. Increased plasma concentrations of TGF-b1 after hormone replacement therapy. J Intern Med 2000;247:279-285. (Pubitemid 30108363)
9. Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008;90:642-672.
10. Eilertsen AL, Hoibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 2005;52:111-118. (Pubitemid 41368033)
11. Morin-Papunen L, Martikainen H, McCarthy MI, Franks S, Sovio U, Hartikainen AL, Ruokonen A, Leinonen M, Laitinen J, Jarvelin MR, et al. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. Am J Obstet Gynecol 2008;199:529e1-529e10.
12. White T, Ozel B, Jain JK, Stanczyk FZ. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 2006;74:293-296. (Pubitemid 44373883)
13. Merki-Feld GS, Imthurn B, Seifert B. Effects of the progestagen-only contraceptive implant Implanon on cardiovascular risk factors. Clin Endocrinol (Oxf) 2008;68:355-360. (Pubitemid 351257852)
14. Merki-Feld GS, Imthurn B, Seifert B. Effects of the progestagen-only contraceptive implant Implanon on transforming growth factor beta1 and endothelin-1. Horm Metab Res 2008;40:692-669.
15. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990;7:147-159. (Pubitemid 20198145)
16. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-771. (Pubitemid 34633846)
17. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007;49:1455-1461. (Pubitemid 46809394)
18. Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. BMJ 1991;303:694.
19. Kip KE, Marroquin OC, Shaw LJ, Arant CB, Wessel TR, Olson MB, Johnson BD, Mulukutla S, Sopko G, Merz CN, et al. Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am Heart J 2005; 150:900-906. (Pubitemid 41607761)
20. Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, Herrington DM, Barrett-Connor E, Greendale GA. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Am J Med 2006;119:167 e1-167 e8.
21. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008;54:24-38. (Pubitemid 351182593)
22. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006;13:643-650. (Pubitemid 44079534)
23. Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008;93:1702-1710. (Pubitemid 351656508)
24. Lakoski SG, Herrington DM. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric 2005;8:317-326. (Pubitemid 41617480)
25. Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sa MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception 2009;80:519-526.
26. Guerre-Millo M. Adiponectin: an update. Diabetes Metab 2008;34:12-18.
27. Luque-Ramirez M, Alvarez-Blasco F, Escobar-Morreale HF. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients. Obesity (Silver Spring) 2009;17:3-9. (Pubitemid 50324549)
28. Tonstad S, Thorsrud H, Torjesen PA, Seljeflot I. Do novel risk factors differ between men and women aged 18 to 39 years with a high risk of coronary heart disease? Metabolism 2007;56:260-266. (Pubitemid 46074075)
29. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007;27:2094-2099. (Pubitemid 350287235)
30. Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004;69:271-278. (Pubitemid 38366457)